Cantargia AB (publ) (CANTA) Q2 2026 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Cantargia Ab.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.191 -- 00:00:05.032 Good afternoon and welcome to Kantarga's presentation of the second quarter and first 00:00:05.032 -- 00:00:08.773 half year report for 2026. 00:00:08.814 -- 00:00:14.075 My name is Hilde Steininger, Chief Executive Officer at Kantarga, and I'm joined today 00:00:14.075 -- 00:00:18.236 by our Chief Financial Officer, Patrik Renblad. 00:00:18.236 -- 00:00:23.798 Today, I will take you through the operational and strategic progress during the quarter, 00:00:23.798 -- 00:00:28.603 including our clinical development plans and pipeline priorities. 00:00:28.603 -- 00:00:33.347 Patrick will then present the financial results for the second quarter and the first 00:00:33.347 -- 00:00:38.451 six months of 2026 before I return with a brief summary and we 00:00:38.451 -- 00:00:40.753 open up for questions. 00:00:40.753 -- 00:00:44.356 The central theme of today 00:00:44.356 -- 00:00:49.921 is how Kantarga continues to build on its leadership in IL-1 RAP antibody 00:00:49.921 -- 00:00:55.166 development with Nadenolamab as our lead oncology asset 00:00:55.166 -- 00:00:57.270 and with new opportunity 00:00:57.270 -- 00:01:02.433 emerging both in pancreatic cancer and hematologic malignancies. 00:01:02.433 -- 00:01:04.713 Next slide. 00:01:05.755 -- 00:01:11.077 Before we begin, I'd like to remind everybody that today's presentation 00:01:11.077 -- 00:01:13.559 contains forward-looking 00:01:13.559 -- 00:01:18.982 statements. These statements are subject to risk and uncertainties, and actual results 00:01:18.982 -- 00:01:22.303 may differ from those expressed or implied. 00:01:22.303 -- 00:01:27.341 We therefore encourage you to read through the Safe Harbor statement and the risk factor 00:01:27.341 -- 00:01:30.702 described in Contargia's publi...